

• **Name:** Gun Min Kim

• **Current Position:** Assistant Professor

• **Country:** South Korea

• **Educational Background:**

1996-2002 Bachelor's Degree,

Yonsei University College of Medicine, Seoul, Korea

2009-2011 Master's Degree of Medical Science,

Yonsei University College of Medicine, Seoul, Korea

2014~ Ph.D. Course of Medical Science,

Yonsei University College of Medicine, Seoul, Korea

• **Professional Experience:**

2005-2006 Rotating Internship, Severance Hospital

2007-2011 Resident in Internal Medicine, Severance Hospital

2011-2012 Clinical Fellow, Yonsei Cancer Center, Severance Hospital

2012-2013 Medical Director, Medical & Life Cycle Management, Samsung Bioepis

2014-2018 Clinical assistant professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine

2018~ Assistant professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine

• **Professional Organizations:** Yonsei University College of Medicine

• **Main Scientific Publications:**

1. A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-dense Doxorubicin/cyclophosphamide. Kim GM, Kim JH, Jeong JH, Cho YU, Kim SI, Park S, Park HS, Kim JY, Sohn J. Cancer Res Treat. 2018 Sep 19

2. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). Kim JY, Im SA, Jung KH, Ro J, Sohn J, Kim JH, Park YH, Kim TY, Kim SB, Lee KS, Kim GM, Kim SH,

- Kim S, Ahn JS, Lee KH, Ahn JH, Park IH, Im YH; breast cancer committee of Korean Cancer Study Group (KCSG). *Eur J Cancer*. 2018 Nov;103:127-136
3. Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma. Na K, Lee JY, Sung JY, Kim GM, Koo JS, Kim HS. *Virchows Arch*. 2018 Jun
4. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH; Korean Cancer Study Group (KCSG). *Eur J Cancer*. 2017 Nov;86:385-393
5. Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results. Park HS, Park SJ, Kim JY, Kim S, Ryu J, Sohn J, Park S, Kim GM, Hwang IS, Choi JR, Kim SI. *Ann Surg Treat Res*. 2017 May;92(5):331-339.
6. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. Kim GM, Kim SJ, Song SK, Kim HR, Kang BD, Noh SH, Chung HC, Kim KR, Rha SY. *BMC Cancer*. 2017 Apr 20;17(1):283
7. A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. Kim GM, Reid T, Shin SJ, Rha SY, Ahn JB, Lee SS, Chung HC. *Invest New Drugs*. 2017 Dec;35(6):773-781.
8. Chemotherapy-induced irreversible alopecia in early breast cancer patients. Kim GM, Kim S, Park HS, Kim JY, Nam S, Park S, Kim SI, Kim D, Sohn J. *Breast Cancer Res Treat*. 2017 Mar 21
9. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Park HS, Sohn J, Kim SI, Park S, Park HS, Gho SG, Chung HC, Paik S, Kim GM. *Breast Cancer Res Treat*. 2017 Feb 27
10. Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. Kim CG, Sohn J, Chon H, Kim JH, Heo SJ, Cho H, Kim IJ, Kim SI, Park S, Park HS, Kim GM *J Breast Cancer*. 2016 Mar;19